SG11201503878XA - Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses - Google Patents
Monoclonal antibodies targeting neutralizing epitopes on h7 influenza virusesInfo
- Publication number
- SG11201503878XA SG11201503878XA SG11201503878XA SG11201503878XA SG11201503878XA SG 11201503878X A SG11201503878X A SG 11201503878XA SG 11201503878X A SG11201503878X A SG 11201503878XA SG 11201503878X A SG11201503878X A SG 11201503878XA SG 11201503878X A SG11201503878X A SG 11201503878XA
- Authority
- SG
- Singapore
- Prior art keywords
- monoclonal antibodies
- influenza viruses
- antibodies targeting
- neutralizing epitopes
- targeting neutralizing
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727927P | 2012-11-19 | 2012-11-19 | |
| PCT/SG2013/000366 WO2014077777A1 (en) | 2012-11-19 | 2013-08-23 | Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503878XA true SG11201503878XA (en) | 2015-06-29 |
Family
ID=50731547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503878XA SG11201503878XA (en) | 2012-11-19 | 2013-08-23 | Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9637537B2 (en) |
| EP (2) | EP3348568B1 (en) |
| CN (1) | CN105555802B (en) |
| SG (1) | SG11201503878XA (en) |
| WO (1) | WO2014077777A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109988236B (en) * | 2017-12-30 | 2022-04-01 | 中国科学院天津工业生物技术研究所 | Application of influenza virus antibody |
| CN111154728A (en) * | 2020-01-13 | 2020-05-15 | 扬州大学 | Monoclonal antibody and method for detecting H7N9 subtype avian influenza virus HA polypeptide competitive inhibition ELISA antibody |
| WO2022061216A1 (en) * | 2020-09-21 | 2022-03-24 | Icahn School Of Medicine At Mount Sinai | Archaea l30 proteins as universal influenza virus therapeutics |
| CN115873104B (en) * | 2022-08-09 | 2023-07-14 | 华南农业大学 | Nanometer antibody M124 for H7 subtype avian influenza virus and application thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5843708A (en) | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| CA2657681C (en) | 2006-07-14 | 2019-03-19 | Ac Immune S.A. | Humanized antibodies against beta amyloid protein |
| SG183031A1 (en) | 2007-09-13 | 2012-08-30 | Temasek Life Sciences Lab Ltd | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof |
| US8871207B2 (en) * | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
-
2013
- 2013-08-23 EP EP18158352.7A patent/EP3348568B1/en active Active
- 2013-08-23 US US14/442,626 patent/US9637537B2/en active Active
- 2013-08-23 SG SG11201503878XA patent/SG11201503878XA/en unknown
- 2013-08-23 CN CN201380070832.4A patent/CN105555802B/en active Active
- 2013-08-23 WO PCT/SG2013/000366 patent/WO2014077777A1/en active Application Filing
- 2013-08-23 EP EP13855450.6A patent/EP2920207B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105555802B (en) | 2020-08-28 |
| US20160257731A1 (en) | 2016-09-08 |
| US9637537B2 (en) | 2017-05-02 |
| EP2920207A4 (en) | 2016-06-15 |
| EP2920207A1 (en) | 2015-09-23 |
| EP2920207B1 (en) | 2018-03-21 |
| CN105555802A (en) | 2016-05-04 |
| WO2014077777A1 (en) | 2014-05-22 |
| EP3348568B1 (en) | 2019-05-15 |
| EP3348568A1 (en) | 2018-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202109290B (en) | High-concentration monoclonal antibody formulations | |
| HK1252895A1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| BR112015008635A2 (en) | broadly neutralizing anti-HIV antibodies. | |
| EP2857419A4 (en) | Antigen-binding molecule for eliminating aggregated antigens | |
| ZA201406227B (en) | Humanized antibodies that recognize alpha-synuclein | |
| EP2663334A4 (en) | Antibodies directed against influenza | |
| EP2768858A4 (en) | Antibodies directed against influenza | |
| EP2828292A4 (en) | Jcv neutralizing antibodies | |
| DK2828284T3 (en) | JCV NEUTRALIZING ANTIBODIES | |
| ZA201507251B (en) | Antibodies targeting m-csf | |
| SG11201503878XA (en) | Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses | |
| SI2814843T1 (en) | Il-beta neutralizing human monoclonal antibodies | |
| SG11201400100SA (en) | Dengue-virus serotype neutralizing antibodies | |
| SG11201403773WA (en) | Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3 | |
| SG11201503432SA (en) | Monoclonal antibody against muramyl peptides |